Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 471
- Registration Number
- NCT00510952
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico
An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2009-08-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1131
- Registration Number
- NCT00510211
- Locations
- 🇬🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece
Olanzapine Treatment of Patients With Bipolar I Disorder
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2011-05-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 514
- Registration Number
- NCT00510146
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Atomoxetine hydrochlorideDrug: Placebo
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2010-04-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 445
- Registration Number
- NCT00510276
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico
Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT00509821
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
- Conditions
- Colorectal Cancer
- Interventions
- Biological: IMC-A12Biological: cetuximab
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 65
- Registration Number
- NCT00503685
- Locations
- 🇺🇸
ImClone Investigational Site, New York, New York, United States
Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 92
- Registration Number
- NCT00503399
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 434
- Registration Number
- NCT00497770
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico
Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression
- Conditions
- Depression
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2007-07-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 940
- Registration Number
- NCT00494377
- Locations
- 🇦🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2009-11-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 442
- Registration Number
- NCT00494013
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan